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1015-9584/Copyright ª 2014, Asian SuSummary Intravesical Bacillus CalmetteeGue´rin (BCG) has been a proven and effective
immunotherapy treatment for superficial transitional cell carcinoma (TCC) of the bladder,
especially for high-grade tumors and carcinoma in situ. Nevertheless, significant side effects
are associated with BCG instillations, including fever, myalgia, malaise, dysuria, hematuria,
and irritable lower urinary tract symptoms. We herein report the case of a patient who devel-
oped Reiter’s syndrome following intravesical BCG instillations. A 39-year-old Chinese man
presented with a 3-week history of dysuria, suprapubic pain, and pain at the tip of the penis
postmicturition. Initial investigations revealed that he had microhematuria, and an ultrasound
with computed tomography scan of the abdomen showed a bladder mass. Transurethral resec-
tion of the bladder tumor was performed and the patient received a single dose of intravesical
mitomycin postoperatively. Results of histopathological examination revealed high-grade
bladder TCC (G3pT1), and the patient was managed with intravesical BCG for 2 weeks
following the surgery. Four weekly cycles of BCG were administered uneventfully; however,
before the fifth instillation, the patient complained of urethral discharge, bilateral conjuncti-
vitis, and low back pain. Reiter’s syndrome was diagnosed as a rare but known complication of
BCG instillation and the BCG immunotherapy was withheld. The patient was treated with
nonsteroidal antiinflammatory drugs (for back pain) and eye ointment (for conjunctivitis)
and his condition improved. This case report of Reiter’s syndrome should be highlighted as a
rare but significant complication of BCG immunotherapy and urologists should have a high in-
dex of suspicion to diagnose this rare complication.
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+ MODEL1. Introduction
The classical triad of urethritis, conjunctivitis, and
arthritis often prompts the clinician toward the diagnosis of
Reiter’s syndrome. This syndrome is often described
following urinary, respiratory, venereal, or gastrointestinal
infections. However, in our patient, we diagnosed the
syndrome following intravesical installations of Bacillus
CalmetteeGue´rin (BCG) for superficial bladder transitional
cell carcinoma (TCC). Fortunately, we recognized this un-
common syndrome and treated the patient with appro-
priate medications. We therefore recommend that
clinicians should be highly vigilant and suspicious of Reiter’s
syndrome following intravesical BCG immunotherapy in
patients.
2. Case report
A 39-year-old Chinese mechanic presented with a 3-week
history of painful micturition and microhematuria. The
patient felt pain at the tip of the penis at the end of
micturition and it lasted for a few minutes postmicturition;
in addition, a vague pain was also felt at the suprapubic
region when the bladder was full. The patient did not have
any obvious urethral discharge nor any previous infections
with sexually transmitted diseases (STDs). He was generally
in good health with no significant comorbidities, but he was
a smoker of 20 pack-years. The general and abdominal
clinical examination results were unremarkable. Initial in-
vestigations confirmed microhematuria on urine microscopy
and an abdominal ultrasound revealed a suspicious lesion at
the dome of the bladder.
Abdominal computed tomography scan confirmed the
bladder lesion with no extra vesical extension. A subse-
quent flexible cystoscopy showed a solid papillary lesion at
the dome of the bladder (Fig. 1) and two smaller lesions in a
background of inflamed urothelium (Fig. 2). The patient
underwent transurethral resection of the bladder tumorFigure 1 Cystoscopic view of bladder lesion.
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of a single dose of mitomycin C in the recovery suite. The
histopathological report confirmed high-grade 3 TCC of the
bladder with no carcinoma in situ and no evidence of
muscularis propria invasion. He made an uneventful re-
covery and 2 weeks later an intravesical course of BCG was
initiated to reduce the risk of recurrence and progression of
the bladder tumor. He received weekly intravesical instal-
lation of BCG (81 mg/week) and received 4 weeks of
installation uneventfully. However, 2 days before the fifth
instillation, the patient reported milky urethral discharge,
bilateral red sore eyes, and low backache associated with
asymmetrical arthralgias of the hands and feet. There were
no preceding flu-like symptoms, lethargy, fever, or any
gastrointestinal or urinary tract infections and he had no
previous rheumatologic disorders. On examination, bilat-
eral conjunctivitis was identified (Fig. 3) and the patient
had limited back movement due to pain. There were no
stigmata of genital cutaneous lesions. Blood test results
were largely unremarkable, urine culture did not reveal any
bacterial growth, and urethral smear was negative. Routine
tests for STD were negative. We suspected Reiter’s syn-
drome and BCG treatment was deferred. The patient was
then referred to a rheumatologist and an ophthalmologist
for their opinions, who confirmed the diagnosis as Reiter’s
syndrome. The patient was treated symptomatically with
nonsteroidal antiinflammatory drugs (NSAIDs) for the back
pain and with chloramphenicol eye ointment for conjunc-
tivitis. He was then closely monitored in order to initiate
treatment with steroids and isoniazid if there was no
spontaneous improvement. Fortunately, the conjunctivitis
subsided after 8 days of treatment and his backache
resolved after 3 weeks. We decided to stop further BCG
treatment, and a subsequent cystoscopy check revealed
only generalized inflammation with no signs of recurrence.
The subsequent follow-up cystoscopies to detect re-
currences were essentially normal. Once these aforemen-
tioned symptoms resolved, no recurrences of
conjunctivitis, arthralgias, or any further urethral discharge
was noted.Figure 2 Cystoscopic view of the inflamed urothelium of the
bladder.
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Figure 3 Bilateral conjunctivitis.
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Reiter’s syndrome, which is also known as reactive arthritis,
is the classic triad of conjunctivitis, urethritis, and arthritis
occurring after an infection, particularly following an
infection of the urogenital or gastrointestinal tract.1 Clas-
sically, this syndrome has been described following urinary,
respiratory, venereal, or gastrointestinal infections. How-
ever, in our case, the patient developed the syndrome
following intravesical BCG instillations for superficial
bladder TCC. In a recent review of reactive arthritis
following BCG immunotherapy, there have been a few case
reports of Reiter’s syndrome following intravesical BCG
immunotherapy.2
The infamous phrase of “can’t see, can’t pee, and
can’t climb a tree” often gets associated with this syn-
drome due to the corresponding symptoms of conjuncti-
vitis, urethritis, and arthritis. In most cases this syndrome
tends to affect adults, although children have also been
reported to be affected. In general, the syndrome has a
significant male preponderance and often occurs in the
third decade of life.
The pathophysiology of this syndrome is largely thought
to be due to immune and infectious components.
Numerous organisms have been associated with the pre-
ceding cause of Reiter’s syndrome and its close association
with HLA-B27 may lead to cross-reactivity, a situation in
which the antibodies developed against these infections
will also have the affinity for HLA-B27.1 Likewise, in the
case of BCG immunotherapy-induced Reiter’s syndrome,
both local and systemic immune mechanisms have been
thought to induce the molecular mimicry mechanism of
the disease.2
Clinical manifestations of Reiter’s syndrome can be
quite variable and these include the urogenital, rheuma-
tologic, ophthalmologic, dermatologic, and visceral sys-
tems. However, the classical triad of urethritis,
conjunctivitis, and arthritis only occurs in about one third
of patients.3 In our case, the patient presented with the
classical triad of urethral discharge, conjunctivitis, and
back pain, which helped us to diagnose the syndrome
promptly. In fact, back pain has been noted to be present in
49% of the patients at the onset,4 whereas conjunctivitisPlease cite this article in press as: Ng KL, Chua CB, Reiter’s syndro
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observed in up to 60% of patients.5
Often the diagnosis of Reiter’s syndrome will be based
on thorough medical history and systematic clinical exam-
ination, with a high index of suspicion when the triad of
symptoms is noticed. There is no single confirmatory labo-
ratory or radiological test that can confirm diagnosis. In
addition, there are also differential diagnoses of gout,
gonococcal urethritis, and psoriatic arthritis that must be
excluded. In our patient, the syndrome was diagnosed
based on multiple consultations with the ophthalmologist
and rheumatologist.
Treatment of Reiter’s syndrome usually revolves around
providing symptomatic relief and this includes bed rest,
NSAIDs, and eye ointments. These general symptomatic
measures often will provide the remission of symptoms.
Occasionally, steroids with or without isoniazid or rifam-
picin may be started if the symptoms prolong or worsen.
There is no consensus with regard to the use of antibiotics,
especially in the usual cases preceded by infections, but in
our patient, who developed Reiter’s syndrome following
intravesical BCG instillations, no antibiotics were needed.
In cases of BCG-induced Reiter’s syndrome, cessation of the
intravesical BCG immunotherapy is perhaps the most
important treatment together with medications aimed at
symptomatic relief.
The prognosis of Reiter’s syndrome is variable, but most
cases achieve spontaneous resolution of symptoms by a few
weeks, and in rare cases may progress to chronic illness.
Our patient has had no relapse of Reiter’s syndrome and
fortunately, despite not completing the full 6-week course
of intravesical BCG, he has not had recurrence of bladder
tumor as well.4. Conclusion
This case report of Reiter’s syndrome should be highlighted
as a rare but significant complication of BCG immuno-
therapy and urologists should have a high index of suspicion
to diagnose this rare complication. Early recognition of this
syndrome will lead to prompt treatment, which includes
cessation of BCG immunotherapy and symptomatic relief of
the conjunctivitis and arthritic pain, thereby reducing the
need for immunosuppressive therapy and progression to
chronic arthritis.References
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